Orchestra BioMed First Quarter 2026 Financial Results and Business Updates
Orchestra BioMed Holdings, Inc. announced its first quarter financial results for 2026, highlighting advances in its pivotal-stage cardiovascular programs, particularly Atrioventricular Interval Modulation Therapy and Virtue Sirolimus AngioInfusion Balloon. The company reported significant progress in clinical trials and collaborations, noting that AVIM Therapy is a bioelectronic treatment for hypertension, and Virtue SAB is a non-coated drug delivery system designed for atherosclerotic artery disease treatment. The CEO expressed optimism regarding upcoming milestones and regulatory submissions, supported by a strong financial position.
NEW HOPE, Pa., May 12, 2026 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced financial results for the first quarter ended March 31, 2026, and provided a business update highlighting momentum across the Company’s pivotal-stage programs for Atrioventricular Interval Modulation (“AVIM”) Therapy and Virtue® Sirolimus AngioInfusion™ Balloon (“Virtue SAB”) supported by the Company’s strong balance sheet.